MedTrace Logo

Management of Migraine Using Enerumab and Traditional Therapy at the Time of COVID-19

NCT05052008 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2021-09-21

No results posted yet for this study

Summary

The objective of this study was to assess the efficacy of erenumab on frequency of monthly migraine days in adults at baseline, 3 months and 6 months, disability in patients with chronic migraine and on post covid migraine severity

Conditions

  • Migraine Disorders

Interventions

DRUG

Erenumab

Erenumab is monoclonal antibody used for management of migraine

Sponsors & Collaborators

  • Fayoum University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-15
Primary Completion
2021-08-10
Completion
2021-09-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05052008 on ClinicalTrials.gov